Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

ConditionsChildhood Acute Lymphoblastic Leukemia Childhood Lymphoblastic Lymphoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age2-22

SponsorMayo Clinic

About this trial

This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).

Eligibility criteria

Qualifiers

Age 2-21.5 years

Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma

Planned treatment with Cal-PEG

Informed consent obtained from parents or guardians

Disqualifiers

Pre-existing coagulation disorders

Known hypersensitivity to asparaginase products

Liver failure

Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)

Trial design

Treatments tested in this trial

Non-Interventional Study

Treatment groups

15 Participants

are divided into 1 treatment group

Sponsors and collaborators

Mayo Clinic

Lead sponsor

Source ClinicalTrials.gov